Penumbra Inc (PEN) — SEC Filings

Penumbra Inc (PEN) — 26 SEC filings. Latest: 425 (May 7, 2026). Includes 8 8-K, 6 SC 13G/A, 5 10-Q.

View Penumbra Inc on SEC EDGAR

Overview

Penumbra Inc (PEN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Penumbra Inc. reported robust financial performance for the nine months ended September 30, 2025, with revenue increasing to $1,018.28 million, up from $879.097 million in the prior year, representing a 15.8% growth. The company swung from a net loss of $19.671 million in the nine months ended Septe

Sentiment Summary

Across 26 filings, the sentiment breakdown is: 2 bullish, 24 neutral. The dominant filing sentiment for Penumbra Inc is neutral.

Filing Type Overview

Penumbra Inc (PEN) has filed 2 425, 8 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to May 2026.

Filings by Year

2026 · 2025 · 2024

Recent SEC Filings (26)

Penumbra Inc SEC Filing History
DateFormDescriptionRisk
May 7, 2026425425 Filing
May 7, 20268-K8-K Filing
Apr 22, 2026425425 Filing
Nov 5, 202510-QPenumbra Swings to Profit on Strong Revenue Growth, Absence of Impairmentlow
Aug 27, 20258-KPenumbra Inc. Board Changes and Officer Compensationlow
Jul 29, 202510-QPenumbra's Q2 Revenue Jumps 15% to $322M, Net Income Up 31%medium
May 30, 20258-KPenumbra Inc. Files 8-K: Governance and Shareholder Matterslow
Apr 23, 20258-KPenumbra Inc. Files 8-K on Financialslow
Apr 16, 2025DEF 14APenumbra Inc. Files 2025 Proxy Statementlow
Feb 21, 20258-KPenumbra Inc. Files 8-K: Officer/Director Changes & Compensationmedium
Feb 18, 202510-KPenumbra Inc. Files 2024 10-Kmedium
Nov 14, 2024SC 13G/ASC 13G/A Filing
Nov 12, 2024SC 13G/ASC 13G/A Filing
Oct 30, 202410-QPenumbra Inc. Files Q3 2024 10-Q Reportlow
Aug 13, 20248-KPenumbra Inc. Files 8-K Reportlow
Jul 30, 202410-QPenumbra Inc. Files Q2 2024 10-Q Financial Reportlow
Jun 7, 20248-KPenumbra Inc. Files 8-K on Shareholder Vote Matterslow
May 7, 202410-QPenumbra Inc. Files 10-Q for Q1 2024low
Apr 24, 2024DEF 14APenumbra Inc. Announces 2024 Annual Meeting of Stockholders on June 5low
Mar 21, 20248-KPenumbra Inc. Changes Auditorsmedium

Risk Profile

Risk Assessment: Of PEN's 17 recent filings, 0 were flagged as high-risk, 4 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Penumbra Inc Financial Summary (10-Q, Nov 5, 2025)
MetricValue
Revenue$1,018.28M
Net Income$130.344M
EPS$3.32
Cash Position$321.029M
Operating Margin12.77%
Total Assets$1,744.369M

Key Executives

  • Chief Executive Officer
  • Dr. Aris T. Papageorge
  • Abigail P. Johnson

Industry Context

Penumbra operates in the highly innovative and competitive medical device sector, specifically focusing on neuro and vascular interventions. Key trends include the increasing demand for minimally invasive procedures, advancements in AI-driven surgical tools, and a growing focus on treating complex conditions like ischemic stroke and venous thromboembolism. The market is characterized by significant R&D investment and a rigorous regulatory environment.

Top Tags

Medical Devices (4) · filing (3) · medical-devices (3) · 10-Q (3) · financials (3) · institutional-ownership (3) · amendment (3) · Revenue Growth (2) · governance (2) · 10-K (2)

Key Numbers

Penumbra Inc Key Metrics
MetricValueContext
Revenue$1.018BIncreased by 15.8% from $879.097M in 2024 to $1.018B in 2025 for the nine-month period.
Net Income$130.344MSwung from a net loss of $19.671M in 2024 to a net income of $130.344M in 2025 for the nine-month period.
Impairment Charge$76.945MAbsence of this charge in 2025 significantly contributed to net income improvement compared to 2024.
Net Cash Provided by Operating Activities$152.179MIncreased from $117.373M in 2024 to $152.179M in 2025 for the nine-month period.
Purchases of Marketable Investments$146.648MSignificant investing activity contributing to the decrease in cash and cash equivalents.
Q2 2025 Revenue$322.0MIncreased from $280.0M in Q2 2024, a 15% growth.
Q2 2025 Net Income$36.7MIncreased from $28.0M in Q2 2024, a 31% growth.
Revenue Growth15%Percentage increase in revenue from Q2 2024 to Q2 2025.
Net Income Growth31%Percentage increase in net income from Q2 2024 to Q2 2025.
Common Stock (June 30, 2025)$0.322MReflects an increase from $0.280M at December 31, 2024.
Additional Paid-In Capital (June 30, 2025)$1.367BIndicates strong equity base for future investments.
Filing Date20250416Date the proxy statement was filed with the SEC.
Period of Report20250528The period the proxy statement pertains to.
Fiscal Year End1231Indicates the end of the company's fiscal year.
Fiscal Year2024Reporting period for the 10-K

Forward-Looking Statements

  • {"claim":"FMR LLC will maintain its significant passive stake in Penumbra Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}

Related Companies

ISRG · MDT · SYK

Frequently Asked Questions

What are the latest SEC filings for Penumbra Inc (PEN)?

Penumbra Inc has 26 recent SEC filings from Jan 2024 to May 2026, including 8 8-K, 6 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of PEN filings?

Across 26 filings, the sentiment breakdown is: 2 bullish, 24 neutral. The dominant sentiment is neutral.

Where can I find Penumbra Inc SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Penumbra Inc (PEN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Penumbra Inc?

Key financial highlights from Penumbra Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for PEN?

The investment thesis for PEN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Penumbra Inc?

Key executives identified across Penumbra Inc's filings include Chief Executive Officer, Dr. Aris T. Papageorge, Abigail P. Johnson.

What are the main risk factors for Penumbra Inc stock?

Of PEN's 17 assessed filings, 0 were flagged high-risk, 4 medium-risk, and 13 low-risk.

What are recent predictions and forward guidance from Penumbra Inc?

Recent forward-looking statements from Penumbra Inc include guidance on {"claim":"FMR LLC will maintain its significant passive stake in Penumbra Inc. for the foreseeable future.","entity":"FM.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.